Literature DB >> 21479962

The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.

Wei Hua1, Yu Yao, Yiwei Chu, Ping Zhong, Xiaofang Sheng, Baoguo Xiao, Jingsong Wu, Bojie Yang, Ying Mao, Liangfu Zhou.   

Abstract

To explore the immunogenicity of glioma stem-like cell-associated antigens (SAAs) from sorted or unsorted glioma tumor stem-like cells (TSCs) as well as irradiated TSCs. Two primary human malignant glioma lines (SHG62, SHG66) and U87 cell line were primarily cultured in the serum-free medium (SFM) supplemented with EGF/bFGF. TSCs were identified by their self-renewal, multi-lineage differentiation and tumorigenic activity. To prepare SAAs in vitro, CD133+ TSCs were sorted either by magnetic cell sorting or with irradiation (6 Gy).The cytotoxicity induced by autogenous myeloid dendritic cell (DC)-mediated SAA-specific cytotoxic T lymphocytes (CTLs) was assessed by the Just Another Method test. SHG62, SHG66, and U87 cells contained TSCs. CD133+ SAAs-specific CTLs were significantly more cytotoxic than effector cells loaded with unsorted SAA (P < 0.05). Effector cells loaded with irradiated SAAs were more cytotoxic than those with regular SAAs (P < 0.01). SAAs from CD133+ TSCs and irradiated TSCs provide highly immunogenic antigens. TSCs might be a novel source of antigens for DC vaccination against malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479962     DOI: 10.1007/s11060-011-0572-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Expression of the tumor-rejection antigen SART1 in brain tumors.

Authors:  T Imaizumi; T Kuramoto; K Matsunaga; S Shichijo; S Yutani; M Shigemori; K Oizumi; K Itoh
Journal:  Int J Cancer       Date:  1999-12-10       Impact factor: 7.396

2.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

Authors:  D D Chi; R E Merchant; R Rand; A J Conrad; D Garrison; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

3.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

Authors:  J S Yu; C J Wheeler; P M Zeltzer; H Ying; D N Finger; P K Lee; W H Yong; F Incardona; R C Thompson; M S Riedinger; W Zhang; R M Prins; K L Black
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

Review 4.  Neoplastic stem cells: a novel therapeutic target in clinical oncology.

Authors:  Axel Schulenburg; Herbert Ulrich-Pur; Dietmar Thurnher; Boban Erovic; Stefan Florian; Wolfgang R Sperr; Peter Kalhs; Brigitte Marian; Friedrich Wrba; Christoph C Zielinski; Peter Valent
Journal:  Cancer       Date:  2006-11-15       Impact factor: 6.860

5.  Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

Authors:  Fumiyoshi Okano; Walter J Storkus; William H Chambers; Ian F Pollack; Hideho Okada
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

6.  Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

Authors:  Serena Pellegatta; Pietro Luigi Poliani; Daniela Corno; Francesca Menghi; Francesco Ghielmetti; Blanca Suarez-Merino; Valentina Caldera; Sara Nava; Maria Ravanini; Fabio Facchetti; Maria Grazia Bruzzone; Gaetano Finocchiaro
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

7.  Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.

Authors:  Jie Dai; Bei Liu; Marissa M Caudill; Hong Zheng; Yi Qiao; Ekhard R Podack; Zihai Li
Journal:  Cancer Immun       Date:  2003-01-28

8.  B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells.

Authors:  Yu Yao; Xiaomei Wang; Kunlin Jin; Jianhong Zhu; Yin Wang; Sidong Xiong; Ying Mao; Liangfu Zhou
Journal:  J Neurooncol       Date:  2008-05-14       Impact factor: 4.130

9.  In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.

Authors:  Stephanie E Combs; Daniela Schulz-Ertner; Wilfried Roth; Christel Herold-Mende; Jürgen Debus; Klaus-Josef Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-07-01       Impact factor: 7.038

10.  Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy.

Authors:  M Schmitz; A Temme; V Senner; R Ebner; S Schwind; S Stevanovic; R Wehner; G Schackert; H K Schackert; M Fussel; M Bachmann; E P Rieber; B Weigle
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

View more
  14 in total

Review 1.  Recent advances in therapeutic cancer vaccines.

Authors:  Jeffrey Schlom
Journal:  Cancer Biother Radiopharm       Date:  2012-01-17       Impact factor: 3.099

Review 2.  Cell-based immunotherapy against gliomas: from bench to bedside.

Authors:  M Sarah S Bovenberg; M Hannah Degeling; Bakhos A Tannous
Journal:  Mol Ther       Date:  2013-05-07       Impact factor: 11.454

Review 3.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

4.  Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.

Authors:  Ming Xu; Yu Yao; Wei Hua; Zhebao Wu; Ping Zhong; Ying Mao; Liangfu Zhou; Feifei Luo; Yiwei Chu
Journal:  J Neurooncol       Date:  2014-01-08       Impact factor: 4.130

5.  High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance.

Authors:  Zhe Bao Wu; Lin Cai; Shao Jian Lin; Zhen Kun Xiong; Jiang Long Lu; Ying Mao; Yu Yao; Liang Fu Zhou
Journal:  Neuro Oncol       Date:  2013-07-04       Impact factor: 12.300

Review 6.  A critical overview of long non-coding RNA in glioma etiology 2016: an update.

Authors:  Yuan-Feng Gao; Zhi-Bin Wang; Tao Zhu; Chen-Xue Mao; Xiao-Yuan Mao; Ling Li; Ji-Ye Yin; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Tumour Biol       Date:  2016-09-15

7.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

8.  T cells redirected to EphA2 for the immunotherapy of glioblastoma.

Authors:  Kevin K H Chow; Swati Naik; Sunitha Kakarla; Vita S Brawley; Donald R Shaffer; Zhongzhen Yi; Nino Rainusso; Meng-Fen Wu; Hao Liu; Yvonne Kew; Robert G Grossman; Suzanne Powell; Dean Lee; Nabil Ahmed; Stephen Gottschalk
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

Review 9.  The role of cancer stem cells in the modulation of anti-tumor immune responses.

Authors:  Cristina Maccalli; Kakil Ibrahim Rasul; Mamoun Elawad; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2018-09-24       Impact factor: 15.707

Review 10.  Current vaccine trials in glioblastoma: a review.

Authors:  Linda W Xu; Kevin K H Chow; Michael Lim; Gordon Li
Journal:  J Immunol Res       Date:  2014-04-03       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.